Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2016
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01597297 (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine), which is not on this map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and Balance in Subjects With Multiple Sclerosis
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Maintaining Mobility and Balance in Multiple Sclerosis: A Systematic Review Examining Potential Impact of Symptomatic Pharmacotherapy.CNS drugs · 2025Pooled it
- Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials.Orphanet journal of rare diseases · 2021Pooled it
- Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis.CNS drugs · 2019Pooled it
- Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis.PloS one · 2019Pooled it
- Trial
- Trial
- Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).BMC neurology · 2015Trial
- 4-aminopyridine exerts anxiolytic and pro-cognitive effects in mice model of medial prefrontal cortex ischemia.Metabolic brain disease · 2025Article
- Drug-induced peripheral nerve palsy: a real-world study based on FAERS data from 2004 to the third quarter of 2024.Frontiers in pharmacology · 2025Article
- Investigating the Safety of Fampridine in Patients with Different Stages of Multiple Sclerosis.International journal of preventive medicine · 2025Article
- Performance Measures and Plasma Biomarker Levels in Patients with Multiple Sclerosis after 14 Days of Fampridine Treatment: An Explorative Study.International journal of molecular sciences · 2024Article
- The instrumented single leg stance test detects early balance impairment in people with multiple sclerosis.Frontiers in neurology · 2023Article
- Efficacy of prolonged-release fampridineTherapeutic advances in neurological disorders · 2022Article
- Observational
- Neuroprotective Properties of 4-Aminopyridine.Neurology(R) neuroimmunology & neuroinflammation · 2021Review
- Transcutaneous Spinal Cord Stimulation Enhances Walking Performance and Reduces Spasticity in Individuals with Multiple Sclerosis.Brain sciences · 2021Article
- Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial.Therapeutic advances in neurological disorders · 2021Article
- Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond.CNS drugs · 2018Review
- Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting.Therapeutic advances in neurological disorders · 2018Review
- Spotlight on postural control in patients with multiple sclerosis.Degenerative neurological and neuromuscular disease · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMobility impairment is a common disability in MS and negatively impacts patients' lives.
objectiveEvaluate the effect of prolonged-release (PR) fampridine (extended-release dalfampridine in the United States) on self-assessed walking disability, dynamic/static balance and safety in patients with MS.
methodsMOBILE was a randomised, double-blind, exploratory, placebo-controlled trial. Patients with progressive/relapsing-remitting MS and Expanded Disability Status Scale score of 4.0-7.0 were treated with PR-fampridine or placebo twice daily for 24 weeks. Efficacy endpoints included change from baseline in the 12-item MS Walking Scale (MSWS-12), Timed Up and Go (TUG) test and Berg Balance Scale (BBS).
results132 patients were randomised at 24 sites in six countries. PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks. A higher proportion of patients receiving PR-fampridine versus placebo experienced significant improvements at MSWS-12 improvement thresholds ⩾7 (p = 0.0275), ⩾8 (p = 0.0153) and ⩾9 points (p = 0.0088) and TUG speed thresholds ⩾10% (p = 0.0021) and ⩾15% (p = 0.0262). PR-fampridine was well tolerated.
conclusionsPR-fampridine therapy resulted in early and sustained improvements in broad measures of walking and balance over six months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.